Price Alert

Plus Therapeutics Inc. (PSTV)

NASDAQ: PSTV · Real-Time Price · USD

0.63

0.09 (16.19%)

At close: Aug 15, 2025, 1:26 PM

16.19% (1D)

Bid	0.62
Market Cap	37.92M
Revenue (ttm)	2.34M
Net Income (ttm)	-27.12M
EPS (ttm)	-2.78
PE Ratio (ttm)	-0.23
Forward PE	-1.86
Analyst	Buy

Ask	0.63
Volume	10,162,276
Avg. Volume (20D)	32,111,493
Open	0.60
Previous Close	0.54
Day's Range	0.58 - 0.63
52-Week Range	0.16 - 2.31
Beta	0.67

About PSTV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PSTV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PSTV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

New

Plus Therapeutics has released their quartely earnings on Aug 14, 2025:

Revenue of $1.39M misses estimates by $181.8K, with 8.68% YoY growth.

EPS of -0.01 exceeds estimates by 0.10, with 98.59% YoY growth.

Next Earnings Release

Plus Therapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 hours ago New

Plus Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

20 hours ago New

-5.61%

Plus Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

News

1 day ago · zacks.com

Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.71 per share a year ago.

1 month ago · zacks.com

Plus (PSTV) Upgraded to Buy: Here's Why

Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 months ago · zacks.com

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.